The thesis

STIM operates in the healthcare sector with a flagship product for neurohealth conditions. The company's revenue growth is 7.8% year-over-year, but its net margin is -2448.0%. The conviction score is 34/100, indicating a cautious outlook. The analyst consensus rating is BUY, despite a DCF intrinsic value of $-50.

Why now

The current macro context, with the US-China squeeze and Middle East war, may impact STIM's supply chain and profitability. The company's gross margin of 4796.0% and negative P/E ratio of -4.0x make it a compelling story to watch.

What to watch

Investors should monitor STIM's revenue growth and net margin over the next quarter to assess the company's ability to achieve profitability. The company's response to the US-China squeeze and Middle East war will also be crucial in determining its future outlook.

Key risks

STIM faces valuation risk due to its negative intrinsic value and high gross margin. The company is also exposed to macro risks, including trade tensions and geopolitical instability. Execution risk is another concern, given the company's negative net margin.